Cysteamine–bicalutamide combination therapy corrects proximal tubule phenotype in cystinosis

• Published in: EMBO Molecular Medicine 2021, Vol.13 (7)
• Main Authors: Jamalpoor, Amer, Gelder, Charlotte Agh, Yengej, Fjodor A Yousef, Zaal, Esther A, Berlingerio, Sante P, Veys, Koenraad R, Casellas, Carla Pou, Voskuil, Koen, Essa, Khaled, Ammerlaan, Carola Me, Rega, Laura Rita, Welle, Reini En, Lilien, Marc R, Rookmaaker, Maarten B, Clevers, Hans, Klumperman, Judith, Levtchenko, Elena, Berkers, Celia R, Verhaar, Marianne C, Altelaar, Maarten, Masereeuw, Rosalinde, Janssen, Manoe J
• Format: Report
• Language: English
• Subjects: Cysteamine; Cysteine; Cystine; Cystinosis; Development and progression; Genetic aspects; Health aspects; Metabolites
• ISSN: 1757-4676
• DOI: 10.15252/emmm.202013067

Nephropathic cystinosis is a severe monogenic kidney disorder caused by mutations in CTNS, encoding the lysosomal transporter cystinosin, resulting in lysosomal cystine accumulation. The sole treatment, cysteamine, slows down the disease progression, but does not correct the established renal proximal tubulopathy. Here, we developed a new therapeutic strategy by applying omics to expand our knowledge on the complexity of the disease and prioritize drug targets in cystinosis. We identified alpha-ketoglutarate as a potential metabolite to bridge cystinosin loss to autophagy, apoptosis and kidney proximal tubule impairment in cystinosis. This insight combined with a drug screen revealed a bicalutamide-cysteamine combination treatment as a novel dual-target pharmacological approach for the phenotypical correction of cystinotic kidney proximal tubule cells, patient-derived kidney tubuloids and cystinotic zebrafish.